The deregulation of MDM2 and MDM4 has been shown to play a pivotal role in the functional inactivation of p53; therefore, they are attractive molecular targets for the therapeutic reactivation of p53 in cancer cells retaining wild-type p53. This evidence concerns the gene MDM2 and cancer.